Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 3/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16352127 | 0.92 | CETP (0.41) | CARM1PRMT6MAPK14MRGPRX4FFAR4 | |
| SCHEMBL16363228 | 0.88 | CETP (0.38) | CARM1PRMT6MAPK14MRGPRX4FFAR4 | |
| SCHEMBL16363854 | 0.87 | HDAC3 (0.39) | MRGPRX4 | |
| SCHEMBL16352159 | 0.83 | MRGPRX4 (0.39) | CARM1PRMT6MAPK14MRGPRX4FFAR4 | |
| SCHEMBL16363233 | 0.81 | MAOB (0.43) | MMP2MMP9MAOB | |
| SCHEMBL16352173 | 0.80 | CETP (0.46) | CETP | |
| SCHEMBL16363712 | 0.80 | NR4A2 (0.40) | FFAR4CETPMMP2 | |
| SCHEMBL16363847 | 0.79 | MME (0.42) | CETPMAOB | |
| SCHEMBL16352128 | 0.78 | EPHX1 (0.40) | MRGPRX4MMP2MMP9MMP14ADAM17 | |
| SCHEMBL16364157 | 0.77 | MTNR1B (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593136-B2 | Compounds for inhibiting 1-deoxy-D-xylulose-5-phosphate reductoisomerase | THE GEORGE WASHINGTON UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20140378418-A1 | COMPOUNDS FOR INHIBITING 1-DEOXY-D-XYLULOSE-5-PHOSPHATE REDUCTOISOMERASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378418-A1 | COMPOUNDS FOR INHIBITING 1-DEOXY-D-XYLULOSE-5-PHOSPHATE REDUCTOISOMERASE | DCXR, G6PD, GRHPR | CARM1 3926/4885PRMT6 3196/4885MAPK14 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.